Amoy Diagnostics Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 12.36%

Amoy Diagnostics Co Ltd (300685) has an Asset Resilience Ratio of 12.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥277.65 Million

≈ $40.63 Million USD Cash + Short-term Investments

Total Assets

CN¥2.25 Billion

≈ $328.69 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Amoy Diagnostics Co Ltd's Asset Resilience Ratio has changed over time. Check Amoy Diagnostics Co Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Amoy Diagnostics Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300685 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥277.65 Million	12.36%
Total Liquid Assets	CN¥277.65 Million	12.36%

Asset Resilience Insights

Moderate Liquidity: Amoy Diagnostics Co Ltd has 12.36% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Amoy Diagnostics Co Ltd Industry Peers by Asset Resilience Ratio

Compare Amoy Diagnostics Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Chemclin Diagnostics Co. Ltd. A SHG:688468	Diagnostics & Research	15.34%
Monash Ivf Group Ltd AU:MVF	Diagnostics & Research	1.60%
Bcal Diagnostics Ltd AU:BDX	Diagnostics & Research	0.00%
Check Cap Ltd NASDAQ:CHEK	Diagnostics & Research	70.29%
Sonic Healthcare Ltd AU:SHL	Diagnostics & Research	0.13%
Integral Diagnostics Ltd AU:IDX	Diagnostics & Research	0.03%
Australian Clinical Labs Ltd AU:ACL	Diagnostics & Research	4.11%
Cryosite Ltd AU:CTE	Diagnostics & Research	5.65%

Annual Asset Resilience Ratio for Amoy Diagnostics Co Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Amoy Diagnostics Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	17.04%	CN¥351.89 Million ≈ $51.49 Million	CN¥2.06 Billion ≈ $302.15 Million	-7.20pp
2023-12-31	24.25%	CN¥469.12 Million ≈ $68.65 Million	CN¥1.93 Billion ≈ $283.13 Million	+8.54pp
2022-12-31	15.71%	CN¥259.30 Million ≈ $37.94 Million	CN¥1.65 Billion ≈ $241.58 Million	-5.08pp
2021-12-31	20.78%	CN¥315.85 Million ≈ $46.22 Million	CN¥1.52 Billion ≈ $222.41 Million	-2.80pp
2020-12-31	23.58%	CN¥304.86 Million ≈ $44.61 Million	CN¥1.29 Billion ≈ $189.19 Million	+20.71pp
2019-12-31	2.87%	CN¥30.06 Million ≈ $4.40 Million	CN¥1.05 Billion ≈ $153.18 Million	+2.86pp
2018-12-31	0.01%	CN¥90.36K ≈ $13.22K	CN¥818.75 Million ≈ $119.81 Million	--

pp = percentage points

About Amoy Diagnostics Co Ltd

SHE:300685 China Diagnostics & Research

Market Cap

$1.02 Billion

CN¥6.95 Billion CNY

Market Cap Rank

#8719 Global

#2029 in China

Share Price

CN¥17.76

Change (1 day)

-1.39%

52-Week Range

CN¥16.18 - CN¥25.58

All Time High

CN¥57.70